- Home
- CBSH vs IONS Comparison
CBSH vs IONS Comparison
Compare CBSH & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBSH
- IONS
- Stock Information
- Founded
- CBSH 1865
- IONS 1989
- Country
- CBSH United States
- IONS United States
- Employees
- CBSH N/A
- IONS N/A
- Industry
- CBSH Major Banks
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- CBSH Finance
- IONS Health Care
- Exchange
- CBSH Nasdaq
- IONS Nasdaq
- Market Cap
- CBSH 8.0B
- IONS 6.8B
- IPO Year
- CBSH N/A
- IONS 1991
- Fundamental
- Price
- CBSH $54.25
- IONS $70.38
- Analyst Decision
- CBSH Hold
- IONS Strong Buy
- Analyst Count
- CBSH 7
- IONS 21
- Target Price
- CBSH $64.86
- IONS $80.71
- AVG Volume (30 Days)
- CBSH 1.2M
- IONS 2.1M
- Earning Date
- CBSH 10-16-2025
- IONS 10-29-2025
- Dividend Yield
- CBSH 2.03%
- IONS N/A
- EPS Growth
- CBSH 14.48
- IONS N/A
- EPS
- CBSH 4.19
- IONS N/A
- Revenue
- CBSH $1,684,917,000.00
- IONS $966,957,000.00
- Revenue This Year
- CBSH $10.14
- IONS $27.96
- Revenue Next Year
- CBSH $11.08
- IONS $2.33
- P/E Ratio
- CBSH $12.96
- IONS N/A
- Revenue Growth
- CBSH 4.25
- IONS 20.41
- 52 Week Low
- CBSH $51.64
- IONS $23.95
- 52 Week High
- CBSH $72.75
- IONS $76.78
- Technical
- Relative Strength Index (RSI)
- CBSH 46.10
- IONS 47.14
- Support Level
- CBSH $53.31
- IONS $71.48
- Resistance Level
- CBSH $54.28
- IONS $76.78
- Average True Range (ATR)
- CBSH 0.88
- IONS 2.48
- MACD
- CBSH 0.35
- IONS -0.65
- Stochastic Oscillator
- CBSH 93.88
- IONS 32.36
About CBSH Commerce Bancshares Inc.
Commerce Bancshares Inc operates as the bank holding company for Commerce Bank. The bank is engaged in the general banking business, providing a broad range of retail, mortgage banking, corporate, investment, trust, and asset management products and services to individuals, businesses, and municipalities. It operates through three segments: Consumer, Commercial, and Wealth. The Commercial segment provides corporate lending, payment solutions, leasing, international services, and business banking. The Consumer segment covers retail banking, mortgages, installment lending, and card services. The Wealth segment offers trust and estate planning, brokerage, and investment management services.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.